On absorption modeling and food effect prediction of rivaroxaban, a BCS II drug orally administered as an immediate-release tablet
The present work evaluates the food effect on the absorption of rivaroxaban (Riva), a BCS II
drug, from the orally administered commercial immediate-release tablet (Xarelto IR) using …
drug, from the orally administered commercial immediate-release tablet (Xarelto IR) using …
Design and validation of dissolution profile of rivaroxaban by using RP-HPLC method in dosage form
PA Kasad, KS Muralikrishna - Asian Journal of Pharmaceutical …, 2013 - indianjournals.com
Rivaroxaban, anti-coagulant is a novel drug for the prevention of venous thromboembolism
(VTE) in patients who have undergone elective total hip replacement or total knee …
(VTE) in patients who have undergone elective total hip replacement or total knee …
Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and …
DMN Abouhussein… - Journal of liposome …, 2019 - Taylor & Francis
The increasing incidence of venous thromboembolism (VTE) in paediatric population has
stimulated the development of liquid anticoagulant formulations. Thus our goal is to …
stimulated the development of liquid anticoagulant formulations. Thus our goal is to …
Tailoring apixaban in nanostructured lipid carrier enhancing its oral bioavailability and anticoagulant activity
MF Zaky, MA Megahed, TM Hammady, S Gad… - Pharmaceutics, 2022 - mdpi.com
Apixaban (Apx), an oral anticoagulant drug, is a direct factor Xa inhibitor for the prophylaxis
against venous thromboembolism. Apx has limited oral bioavailability and poor water …
against venous thromboembolism. Apx has limited oral bioavailability and poor water …
Evaluation of rivaroxaban amorphous solid dispersions physical stability via molecular mobility studies and molecular simulations
A Kapourani, K Eleftheriadou… - European Journal of …, 2021 - Elsevier
The present study evaluates the effect of molecular mobility and molecular interactions in the
physical stability of rivaroxaban (RIV)–soluplus®(SOL) amorphous solid dispersions (ASDs) …
physical stability of rivaroxaban (RIV)–soluplus®(SOL) amorphous solid dispersions (ASDs) …
Ecofriendly densitometric RP-HPTLC method for determination of rivaroxaban in nanoparticle formulations using green solvents
A literature survey revealed no suitable “reversed phase-high performance thin layer
chromatography (RP-HPTLC)” method for the analysis of rivaroxaban in nanoparticle (NP) …
chromatography (RP-HPTLC)” method for the analysis of rivaroxaban in nanoparticle (NP) …
Application of Design of Experiment in the Optimization of Apixaban-Loaded Solid Lipid Nanoparticles: In Vitro and In Vivo Evaluation
Solid lipid nanoparticles (SLnPs) are usually utilized as lipid-based formulations for
enhancing oral bioavailability of BCS class IV drugs. Accordingly, the objective of this work …
enhancing oral bioavailability of BCS class IV drugs. Accordingly, the objective of this work …
UV spectrophotometric method for determination of the dissolution profile of rivaroxaban
M Çelebier, M KAYNAK, S Altınöz… - Dissolution …, 2014 - avesis.anadolu.edu.tr
© 2014. The United States Pharmacopeial Convention. All rights reserved. Rivaroxaban is
an oral anticoagulant that is the first available orally active direct Factor Xa inhibitor. In this …
an oral anticoagulant that is the first available orally active direct Factor Xa inhibitor. In this …
Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms
E Souri, S Mottaghi, M Zargarpoor… - Acta …, 2016 - akjournals.com
Rivaroxaban is an inhibitor of factor Xa, which is used as an oral anticoagulant for the
prevention of thromboembolism. The objective of this study was to develop a stability …
prevention of thromboembolism. The objective of this study was to develop a stability …